A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™
NCT ID: NCT06320535
Last Updated: 2025-11-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE1
36 participants
INTERVENTIONAL
2024-03-25
2027-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess the Experimental Malaria Vaccines RH5.2-VLP and R21
NCT05357560
A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, With Matrix-M1 Adjuvant
NCT02925403
A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of the Blood-stage Malaria Candidate Vaccines RH5.1 in Matrix-M and R78C in Matrix-M in Healthy UK Adults
NCT05385471
A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, Administered With and Without Matrix-M1
NCT02572388
A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine)
NCT06958198
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In addition to blood sampling throughout the follow-up period, participants will undergo fine needle aspiration of axillary lymph nodes twice during the study, to allow further characterisation of immune responses to this novel vaccine regimen.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
* Two participants will be enrolled first, into Group 1 or 2, with a review of safety data collected up to Day 16 by the DSMC.
* If reactogenicity is acceptable, the remaining participants may be enrolled into Groups 1 and Group 2.
Participants may be recruited to Group 3 at any time.
A second DSMC review will take place 16 days after 10 participants have been recruited in Groups 1 and 2 and 5 participants have been recruited in Group 3
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1: Escalating dose R21/Matrix M™
12 volunteers receiving escalating doses of R21/Matrix M™ adjuvant at days 0, 3, 7, 10, 14, and 56 via intramuscular (IM) injection in the deltoid region of the same arm
R21/Matrix M™ (Group 1)
* 0.50 mcg R21 in 2.75 mcg Matrix-M™ (D0)
* 0.75 mcg R21 in 3.5 mcg Matrix-M™ (D3)
* 1.25 mcg R21 in 6.25 mcg Matrix-M™ (D7)
* 2.5 mcg R21 in 12.5 mcg Matrix-M™ (D10)
* 5 mcg R21 in 25 mcg Matrix-M™ (D14)
* 10 mcg R21 in 50 mcg Matrix-M™ (D56)
Fine needle aspiration (FNA)
Participants in all groups will undergo fine needle aspiration (FNA) of axillary lymph nodes draining vaccination site on Day 77 and Day 105 after initial vaccination.
Group 2: Escalating dose R21/Matrix M™ with delayed booster
12 volunteers receiving escalating doses of R21/Matrix M™ adjuvant at days 0, 3, 7, 10, 14, 168 via intramuscular (IM) injection in the deltoid region of the same arm
R21/Matrix M™ (Group 2)
* 0.50 mcg R21 in 2.75 mcg Matrix-M™ (D0)
* 0.75 mcg R21 in 3.5 mcg Matrix-M™ (D3)
* 1.25 mcg R21 in 6.25 mcg Matrix-M™ (D7)
* 2.5 mcg R21 in 12.5 mcg Matrix-M™ (D10)
* 5 mcg R21 in 25 mcg Matrix-M™ (D14)
* 10 mcg R21 in 50 mcg Matrix-M™(D168)
Fine needle aspiration (FNA)
Participants in all groups will undergo fine needle aspiration (FNA) of axillary lymph nodes draining vaccination site on Day 77 and Day 105 after initial vaccination.
Group 3: Standard dose R21/Matrix-M™
12 volunteers receiving two 10mcg doses of R21 in 50mcg of Matrix M™ adjuvant at days 0 and 56 via intramuscular (IM) injection in the deltoid region of the same arm
R21/Matrix M™ (Group 3)
* 10 mcg R21 in 50 mcg Matrix-M™ (D0)
* 10 mcg R21 in 50 mcg Matrix-M™ (D56)
Fine needle aspiration (FNA)
Participants in all groups will undergo fine needle aspiration (FNA) of axillary lymph nodes draining vaccination site on Day 77 and Day 105 after initial vaccination.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
R21/Matrix M™ (Group 1)
* 0.50 mcg R21 in 2.75 mcg Matrix-M™ (D0)
* 0.75 mcg R21 in 3.5 mcg Matrix-M™ (D3)
* 1.25 mcg R21 in 6.25 mcg Matrix-M™ (D7)
* 2.5 mcg R21 in 12.5 mcg Matrix-M™ (D10)
* 5 mcg R21 in 25 mcg Matrix-M™ (D14)
* 10 mcg R21 in 50 mcg Matrix-M™ (D56)
R21/Matrix M™ (Group 2)
* 0.50 mcg R21 in 2.75 mcg Matrix-M™ (D0)
* 0.75 mcg R21 in 3.5 mcg Matrix-M™ (D3)
* 1.25 mcg R21 in 6.25 mcg Matrix-M™ (D7)
* 2.5 mcg R21 in 12.5 mcg Matrix-M™ (D10)
* 5 mcg R21 in 25 mcg Matrix-M™ (D14)
* 10 mcg R21 in 50 mcg Matrix-M™(D168)
R21/Matrix M™ (Group 3)
* 10 mcg R21 in 50 mcg Matrix-M™ (D0)
* 10 mcg R21 in 50 mcg Matrix-M™ (D56)
Fine needle aspiration (FNA)
Participants in all groups will undergo fine needle aspiration (FNA) of axillary lymph nodes draining vaccination site on Day 77 and Day 105 after initial vaccination.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able and willing (in the Investigator's opinion) to comply with all study requirements.
* Participants of childbearing potential only: must practice continuous effective contraception until the last study visit.
* Agreement to refrain from blood donation for the duration of the study.
* Able and willing to provide written informed consent to participate in the trial.
Exclusion Criteria
* Travel to a clearly malaria endemic locality during the study period or within the preceding six months, as per the CDC website: https://www.cdc.gov/malaria/travelers/country\_table/a.html
* Participation in another research study involving receipt of an investigational medicinal product (IMP) in the 30 days preceding enrolment or 5 half-lives of the investigational medicinal product, whichever is longer, or planned participation during the study period.
* Prior receipt of an IMP likely to impact interpretation of the trial data, as assessed by the Investigator.
* Receipt of any vaccine within 30 days of a study vaccine, with the exception of COVID-19 vaccination.
* Receipt of oral or systemic immunosuppressant medication for more than 14 days in the six months preceding enrolment.
* Receipt of immunoglobulins or blood products (e.g. blood transfusion) in the three months preceding enrolment.
* History of anaphylaxis to vaccination, or allergy likely to be exacerbated by any component of the vaccine or study procedures, including allergy to lidocaine
* Pregnancy, lactation or intention to become pregnant during the study.
* Clinically significant history of chronic disease, including cancer (except basal cell carcinoma or cervical carcinoma in situ), immunodeficiency (including HIV), autoimmune conditions (except mild psoriasis, well-controlled autoimmune thyroid disease, vitiligo or stable coeliac disease), psychiatric disorder, drug or alcohol abuse
* Positive Hepatitis B surface antigen (HBsAg), HIV antibodies or Hepatitis C (HCV) antibodies (except previous HCV vaccine study participants)
* HEMStop score \> or = to 2(30) with abnormal coagulation screen or clinical concern regarding bleeding risk.
* Use of medications that increase the risk of bleeding, as assessed by the clinician, including: warfarin, oral antithrombin agents (e.g. Apixaban), low molecular weight heparin
* Any clinically significant abnormality of screening examination, blood or urine tests
* Any other significant disease, disorder, or finding, which, in the opinion of the Investigator, may put the volunteer at risk, affect the volunteer's ability to participate in the study or impair interpretation of the study data
* Participants unable to be closely followed for social, geographic or psychological reasons.
* Investigator inability to corroborate a participant's medical history via access to NHS electronic records and/or their GP.
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bill and Melinda Gates Foundation
OTHER
University Hospitals Bristol and Weston NHS Foundation Trust
OTHER
University of Oxford
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Susanne Hodgson, DPhil FRCP
Role: PRINCIPAL_INVESTIGATOR
Center for Clinical Vaccinology and Tropical Medicine, University of Oxford
Rajeka Lazarus, DPhil FRCP
Role: PRINCIPAL_INVESTIGATOR
University Hospitals Bristol and Weston Foundation Trust
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre for Clinical Vaccinology and Tropical Meducine, Churchill Hospital, University of Oxford
Oxford, Oxfordshire, United Kingdom
University Hospitals Bristol and Weston NHS Foundation Trust
Bristol, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VAC096
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.